IJARSCT ISSN (Online) 2581-9429 International Journal of Advanced Research in Science, Communication and Technology (IJARSCT) International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal Volume 4, Issue 1, March 2024 Copyright to IJARSCT DOI: 10.48175/568 432 www.ijarsct.co.in Impact Factor: 7.53 Beyond the Surface Unveiling the Intricacies of Floating Drug Delivery Systems Mayur R Waje 1 and Ganesh S Lad 2nd Mangaldeep Institute of Pharmacy, Nipani, Chap. Sambhajinagar, Maharashtra, India 1 Department of Pharmacology, Sandip Institute of Pharmaceutical Science, Maharashtra, India 2 Corresponding author: Mayur R Waje wajemayur5@gmail.com Abstract: Writing an overview on the FDDS served the goal of comprehending the fundamentals of drifting as a means of achieving stomach retention. Both the effervescent and inertvarieties of floating tablets are created using various methods based on buoyancy principles in the production of FDDS. API which are unstable at the lower intestine environment, have a restricted absorptionwindow at the upper GIT, are less soluble in higher pH values, and are active locally can be delivered using FDDS. The technique of design in a floating single unit and several units system, the physical & formulation, and variable impacting stomach retain are all included in the development of FDDS. Reviewing numerous in-vitro and in-vivo procedures with an eye on performance and use in FDDS, the review concentrates on and summarizes these methods. When an appropriate component and gas-generating agent are included, it is possible to administer floating dosage forms in formsthat are not intended for oral administration, such as tablets and capsules. The method is helpful in solving a number of issues that came up when developing drug dosages. Along with current and unique advancements, the review paper sheds light on several strategies employed at development of floating Forms of dosage. Keywords: FDDS, GIT, Gastric retention, Bioavailability, prolong release, in vitro buoyancy I. INTRODUCTION Any drug delivery system's goal is to provide a therapeutic dose of the medication at theappropriatelocation within the body so that it can be quickly attained and then kept at the targeted concentration. Not every medication or therapeutic agent ingested orally is absorbed evenly throughout the GIT. Certain medications are only absorbed in a certain area of the Gastroretentive tract. One of the cutting-edge methods for oral sustained release medication delivery is known as FDDS. Drugs those have narrow absorption window and have more solubility in gastric region are suitable candidates for FDDS.FDDS extends the duration of dosage forms' retention in the stomach or upper gastrointestinal system, enhancing the drug's solubility, bioavailability, and therapeutic efficacy. FDDS are designed to keep medication in the stomach and are useful for medications that are poorly soluble or unstable in intestinal fluid. The fundamental working principle of FDDS is to make the dosage less thick than the stomach contents so that it floats atop them. FDDS are hydro dynamically controlled low density systems that have enough buoyancy to float above the stomach's contents and stay buoyant there for an extended amount of time without slowing down the stomach's emptying rate. A straightforward and useful method for achieving prolonged drug release and an extended dosage form's stomach residence duration is the buoyant preparation principle. By simultaneously administering pharmacological agents that delay stomach emptying, solid dosage forms can be managed in their gastrointestinal retention. Other mechanisms that can be used to do this include mucoadheshion, flotation, sedimentation, expansion, and changed shape systems. Low density systems having enough buoyancy to float over the stomach's contents and remain buoyant in the stomach for an extended amount of time are known as floating or dynamically controlled systems. The process of absorbing drugs from the gastrointestinal tract is intricate and diverse. It is commonly known that contact time with the small intestinal mucosa affects how much a medicine is absorbed through the digestive tract. Small intestine transit time is therefore a crucial factor for drugs that are not fully absorbed.